logo

Cytori Therapeutics Inc. (CYTX)



Trade CYTX now with
  Date
  Headline
9/17/2018 9:28:57 AM Cytori Receives FDA Orphan Drug Designation For ATI-1123 Chemotherapy Drug Product Candidate
8/14/2018 4:21:47 PM Cytori Therapeutics Q2 Loss/share $0.59 Vs. Loss $1.94 Year Ago
7/24/2018 7:04:08 AM Cytori Therapeutics Estimates Rights Offering Will Result In About $6.7 Mln In Gross Proceeds
7/16/2018 8:31:10 AM Cytori Reminds Stockholders Rights Offering Expires On July 20
6/28/2018 9:03:49 AM Cytori Announces Publication Of Preclinical Data From Study Using Intravenous Delivery Of Cytori Cell Therapy
6/12/2018 8:33:16 AM Cytori Informs Stockholders Of Key Dates And Terms Related To Announced Rights Offering
5/10/2018 4:25:46 PM Cytori Q1 Net Loss $4.4 Mln Or $0.07 Per Share
4/30/2018 8:33:24 AM Cytori Updates On US Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin
3/8/2018 4:28:20 PM Cytori Therapeutics Q4 Net Loss $4.3 Mln Or $0.10 Per Share
1/22/2018 9:03:10 AM Cytori : Enrollment Completed In Randomized Trial Of Habeo Cell Therapy For Scleroderma And Impaired Hand Function
11/24/2017 9:01:18 AM Cytori Says Rights Offering Oversubscribed By More Than 75%
11/20/2017 9:04:01 AM Cytori Reports Reduction In Fibrosis Parameters In Scar Study
11/16/2017 8:02:50 AM Cytori Announces Bioequivalence Trial Results In Ovarian Cancer At AAPS